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Abstract
Background: Comparative analysis of the cellular biology of the microvasculature in different tissues requires the availability
of viable primary endothelial cells (ECs). This study describes a novel method to isolate primary ECs from healthy organs,
repair blastemas and tumors as examples of non-proliferating and proliferating benign and malignant tissues and their
functional characterization.
Methodology/Principal Findings: Single cell suspensions from hearts, lungs, repair blastemas and tumors were incubated
consecutively with an anti-CD31 antibody and magnetic micro-beads, coupled to a derivative of biotin and streptavidin,
respectively. Following magnetic bead separation, CD31-positive ECs were released by biotin-streptavidin competition. In
the absence of micro-beads, ECs became adherent to plastic surfaces. ECs from proliferating repair blastemas and tumors
were larger and exhibited higher expression densities of CD31, CD105 and CD102 compared to those from non-proliferating
normal tissues such as heart and lung. The expression density of CD34 was particularly high in tumor-derived ECs, and that
of CD54 and CD144 in ECs of repair blastemas. Functionally, ECs of non-proliferating and proliferating tissues differed in
their capacity to form tubes in matrigel and to align under flow conditions.
Conclusions/Significance: This method provides a powerful tool to generate high yields of viable, primary ECs of different
origins. The results suggest that an altered expression of adhesion molecules on ECs in proliferating tissues contribute to
loss of EC function that might cause a chaotic tumor vasculature.
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Introduction
The diffusion limit of oxygen from the capillary to non-vascular
tissue in the body ranges from 100 to 200 mm. Therefore, a dense
network of blood vessels is necessary to provide an adequate
supply of oxygen and nutrients [1,2]. In capillaries, the endothelial
monolayer is the only cell barrier between blood and intercellular
space, stroma and parenchymal cells. Microvascular ECs also
fulfill important functions in wound healing and blood flow
regulation e.g. by preventing thrombosis. Although in adult
organs, the turnover rate of ECs is generally slow [3], in wound
healing, in the female reproductive cycle and during pregnancy
the proliferation of ECs is very high [2,4]. In tumors, the
proliferative capacity of ECs may be a limiting factor for the
growth of tumors [5]. It is also known that the microvascular
architecture of tumors differs from that of normal tissues. Tumor
vessels develop fewer branches, are often tortuous and have
variable diameters and a higher permeability [6].
In contrast to the primary microvasculature, endothelial cell
lines proliferate rapidly in vitro. Therefore, endothelial cell lines
might resemble certain aspects of the tumor microvasculature, but
may not be suitable for studies of normal ECs in adult organs and
tissues.
To investigate functional properties of primary ECs in non-
proliferative normal tissues such as heart or lung or in actively
growing benign and malignant tissues such as healing wounds and
tumors, an extraction of viable primary ECs from the respective
tissue is necessary. This is particularly important in the study of
key pathogenic mechanisms of late functional damage to the
microvasculature in normal and tumor tissues following ionizing
irradiation. On the one hand, low radiation doses of a few Gy can
lead to cardiovascular injury, which has been suggested to be
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related to long-term functional changes in slowly proliferating ECs
[7,8], rather than to a direct killing of ECs, a proliferative failure,
or a loss in clonogenicity, all of which are commonly associated
with radiation-induced DNA damage. On the other hand,
impairment of the proliferative capacity of ECs in the tumor
and its microenvironment is a well-established mechanism that
results in a retarded re-growth of irradiated tumors [9].
In order to identify phenotypic and functional characteristics of
ECs derived from stable, non-proliferating (heart, lung) and
proliferating benign (repair blastema) and malignant tissues
(tumors) of mice of different ages, a novel method was established
that allows the isolation of viable, primary microvascular ECs.
Methods
Animals
Female/male BALB/c and C57Bl/6 mice (Charles River)
within an age range of 4 to 100 weeks were used for the
experiments. Animals were housed in single, ventilated cages
under pathogen-free conditions. All experiments were approved
by the ‘‘Regierung von Oberbayern’’ and were performed in
accordance with institutional guidelines of the Klinikum rechts der
Isar, Technische Universita¨t Mu¨nchen.
Established Cell Lines
CT26 mouse colon adenocarcinoma cells (CT26.WT; ATCC
CRL-2638) were cultured in RPMI 1640 medium containing 5%
v/v heat-inactivated fetal calf serum, 2 mM L-glutamine, antibi-
otics (100 IU/ml penicillin and 100 mg/ml streptomycin), 50 mM
b-mercaptoethanol and non-essential amino acids (16). B16-F0
mouse melanoma cells (B16-F0; ATCC CRL-6322) and a murine
immortalized heart endothelial cell line H5V [10] were cultured in
DMEM medium (Life Technologies, Carlsbad, CA, USA)
containing 10% v/v heat-inactivated fetal calf serum (PAA
Laboratories GmbH, Pasching, Austria) and antibiotics (100 IU/
ml penicillin and 100 mg/ml streptomycin, Life Technologies).
Cells were passaged twice weekly to maintain them under
exponential growth conditions. Cells were regularly screened
and confirmed to be free from mycoplasma contaminations using
an enzyme immunoassay (Roche Diagnostics, Penzberg, Ger-
many).
Tumor Implantation and Repair Blastema Induction
In order to establish tumors in vivo, 16105 viable CT26 or B16-
F0 cells were injected s.c. into the backs of anesthetized 10 week-
old BALB/c or C57Bl/6 mice. Tumor growth was determined
using sonographic measurements (GE Healthare). Mice were
sacrificed when the tumor had reached a volume ranging between
0.3 and 0.4 cm3. In order to induce a repair blastema, 0.5 ml
sterile air and 0.5 ml sterile incomplete Freund’s adjuvant/PBS-
emulsion (1:1) were injected s.c. into the backs of anesthetized 10
week-old C57Bl/6 mice. Three weeks after injection the repair
blastema was dissected.
Isolation of Microvascular ECs from Heart, Lung, Tumor
and Repair Blastema
For each isolation procedure, one to four mice were sacrificed
by craniocervical dislocation. Heart, lung, repair blastema and
tumors of the mice were collected under aseptic conditions. To
reduce contaminations with macrovascular ECs, the left and right
atria were surgically removed from the heart. The tissues were
rinsed intensely in ice-cold PBS (Gibco). After mechanical mincing
with a sterile scalpel blade, tissue fragments with a size of 1 mm3
were transferred into 10 ml of pre-warmed (37uC) digestion
solution consisting of collagenase A (0.5 units/ml; Roche
Penzberg, Germany) diluted in Hanks’ Balanced Salt Solution
(HBSS, Gibco)/10% FCS (PAA). After an incubation period of 45
minutes at 37uC under gentle rotation (2 rpm), the suspension was
dispersed by forcing it through a sterile 18 G injection needle 10
times. The single cell suspension was filtered through a 70 mm cell
strainer (BD Bioscience) and washed twice in 50 ml HBSS/10%
FCS solution with centrifugation at 4006g for 10 min. Following
re-suspension of the final cell pellet in 600 ml ice-cold isolation
buffer (Invitrogen), DSB-X biotin-labeled (Molecular Probes) rat
anti-mouse CD31-antibody (25 ml; 0.5 mg/ml; BD Biosciences,
Heidelberg, Germany) was added and incubated for 10 minutes at
4uC under gentle rotation (3 rpm). After a washing step in ice-cold
isolation buffer (2 ml), the cell pellet was resuspended in 1 ml cold
isolation buffer. FlowComp Dynabeads coated with streptavidin
(75 ml; Invitrogen) were added and incubated for a further 15
minutes at 4uC under gentle rotation (3 rpm). The tube was then
placed in the magnetic separator (Invitrogen). After 2 minutes, the
bead-free, unbound CD31-negative cells were removed from the
cell suspension by pipetting. CD31-positive cells immobilized in
the DSB-X-streptavidin-bead-complex, remained on the wall of
the tube due to the magnetic field (magnet, Invitrogen). After at
least 5 washing steps with isolation buffer (1 ml), cells attached to
beads were resuspended in 1 ml FlowComp release buffer
(Invitrogen) and incubated for 2 minutes at 21uC. By pipetting
the cell suspension 10 times, the cells detached from the beads by
biotin-streptavidin competition. Then the tube was placed in the
magnet separator. After 1 minute, bead-free CD31-positive cells
could be isolated, whereas the beads remained on the wall of the
tube (Figure 1A).
Culture of Primary ECs
Freshly isolated primary microvascular CD31-positive ECs were
counted and 16106 cells were seeded in gelatin (2%; Merck)
coated T12.5 culture flasks. Endothelial Cell Growth Medium
(EGM2, PromoCell) supplemented with 10% FCS, streptomycin
(100 mg/ml) and penicillin (100 U/ml) was exchanged every third
day and cells were passaged when 90% confluence was reached.
For further functional assays, primary ECs in the first or second
passage were used.
Phenotypic Characterization of Primary ECs
Freshly isolated, primary microvascular ECs were phenotypi-
cally characterized by flow cytometry on a FACSCalibur
instrument (BD, Heidelberg, Germany) using the following
fluorescein (FITC), phycoerythrin (PE) or allophycocyanin (APC)
conjugated antibodies: CD31 (PECAM-1, BD Bioscience, clone
MEC 13.3), CD34 (mucosialin, eBioscience, clone RAM34),
CD45 (leukocyte common antigen, BD Bioscience, clone 30-
F11), CD54 (ICAM-1, BD Bioscience, clone 3E2), CD61 (integrin
b3, BD Bioscience, clone 2C9.G2), CD102 (ICAM-2, BD
Bioscience, clone 3C4), CD105 (endoglin, eBioscience, clone
MJ7/18) and CD144 (VE-cadherin, BD Bioscience, clone
11D4.1). Appropriately labeled isotype-matched immunoglobulins
were used as negative controls. Briefly, 0.16106 viable cells were
incubated with the indicated antibodies for 30 min at 4uC in the
dark. Following a washing step in PBS/FCS (10%) cells were
analyzed on a FACSCalibur instrument. Dead cells were excluded
from the analysis by a propidium iodide co-staining and gating
strategy.
Immunohistochemistry and Immunofluorescence
Formalin-fixed tissue was cut and stained with eosin (eosin
y-solution 0.5% aqueos, Merck) and hematoxylin (Mayer’s
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haematoxylin, Dako). For the CD31 staining primary ECs were
seeded into 8-well chamber slides. After adherence, cells were
incubated with rat-anti-mouse CD31 (clone MEC 13.3, 1:100 in
primary antibody diluent) for 1 h at 23uC and goat-anti-rat Alexa
Fluor 594-labeled secondary antibody (1:200 in PBS) for 1 h at
37uC. Nuclei were co-stained with Fluorescent Mounting Medium
(Dako). For the isolectin staining, cells were blocked with PBS/
BSA (0.2%, Sigma) and incubated with isolectin-FITC-labeled
antibody (1:50 in PBS/BSA 0.2%, Vector FL-1201) for 30 minutes
at 4uC. Nuclei were co-stained with Vectashield (Vector Labs). In
order to detect the distribution of capillaries and the percentage of
necrosis/apoptosis, representative microscopy images from the
heart and tumor were recorded with Axioskop 2 plus Axio Cam
MRc5 (Zeiss).
Flow System Cell Alignment Assay
For the analysis of heart and tumor ECs with permanent shear
stress, ECs were used directly after their isolation. 400,000 cells/
channel were seeded into m-slideVI0.4 (IBIDI). After incubation for
2 days at 37uC under static conditions cells were exposed to low
flow conditions at 2 ml/min (3.5 dyn/cm2). A gas mixer,
temperature controller, heating system and pump system (IBIDI)
guaranteed constant conditions. After 1 day the flow was increased
to 4 ml/min (7 dyn/cm2) for additional 4 days and representative
microscopy pictures of ECs were taken using an Axiovert 40C
microscope (Zeiss).
Migration and Tube Formation Assays
10,000 cells were seeded into m-dishes 35 mm, low with
Culture-Insert (IBIDI) in a volume of 70 ml EGM2 medium
supplemented with 10% FCS, Streptomycin (100 mg/ml) and
Penicillin (100 U/ml). Cells were allowed to become adherent at
which time the migration of heart and tumor ECs was captured
on a video and analyzed. For quantitative evaluation of cell
tracking, films were analyzed with WimTaxis (Wimasis, Munich,
Germany). For tube formation, each well of a m-slide Angiogen-
esis (IBIDI) was filled with 10 ml chilled matrigel (BD). After
incubation for 30 min at 37uC, H5V cells (10,000 cells/well),
primary heart ECs (80,000 cells/well) or tumor ECs (20,000
cells/well) in passage 1 were added in 50 ml medium. After 6 h,
images were recorded with an Axiovert 40C microscope (Zeiss).
For quantitative evaluation, representative pictures were ana-
lyzed with WimTube (Wimasis, Munich, Germany). The total
number of branching points and loops per image were
determined.
Statistical Analysis
Comparative analysis of the data was carried out using the
Student’s t-test (two paired and unpaired). The significance levels
were p* #0.05 (5%); p** #0.01 (1%); p*** #0.001 (0.1%). Data
were presented as means of the number (n) of indicated
experiments.
Figure 1. Schematic representation of the isolation procedure of primary, bead-free endothelial cells (ECs). (A) First, DSB-X biotin-
labeled rat anti-mouse CD31-antibody binds to CD31-positive ECs. Subsequently, streptavidin-labeled Dynabeads bind to DSB-X biotin. After
magnetic separation, the Dynabeads are removed by a biotin-streptavidin competition. (B) Separation of CD31-positive H5V cells mixed with CD31-
negative CT26 tumor cells at a ratio of 20:1. The proportion (%) of CD31-positive H5V cells and the mean fluorescence intensity (mfi) remained
unchanged after a simulated digestion step. (C) After separation, the mean fluorescence intensity (mfi) remained stable after digestion (second bar),
but dropped to 17% after bead separation (third bar). (D) The recovery rate of H5V cells after separation was greater 70%.
doi:10.1371/journal.pone.0091808.g001
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Results
Quality Control Experiment
To test the efficiency of the new method, a CD31-positive
mouse endothelial cell line (H5V) and a CD31-negative mouse
colon cancer cell line (CT26) were mixed at a ratio of 1:20. After a
simulated digestion with collagenase (Figure 1B, second bar) and
magnetic bead separation (Figure 1B, third bar) according to the
method described in Figure 1A, the percentage of CD31 positively
stained H5V cells remained unchanged compared to that of
untreated H5V cells. The mean surface density of CD31 - which
remained high after collagenase digestion (Figure 1C, second bar) -
dropped to 17% following CD31-biotin-streptavidin competition
(Figure 1C, third bar). Despite the low density of free CD31
molecules on the cell surface of H5V cells after CD31-biotin-
streptavidin competition, the recovery rate of H5V cells was more
than 70% after the complete separation procedure (Figure 1D). It
is assumed that the recovery rate of primary ECs are higher
because the mean cell surface density of CD31 on heart, repair
blastema and tumor ECs (8568, 479614, 211667) are higher
compared to that of H5V cells (3164). Flow cytometric analysis
revealed that no contaminating CD31-negative tumor (CT26) cells
were present in the CD31-positive fraction (data not shown).
These findings demonstrate that it is possible to recover CD31-
positive ECs from a mixture of different cells with high efficiency
and purity.
Determination of the Yield of ECs from Different Tissues
in Mice of Different Ages
To determine the distribution and density of capillaries and the
fraction of necrotic and apoptotic areas, sections of hearts and
tumors of mice were analyzed by CD31 immunofluorescence and
H&E staining. Viable tumor tissue is characterized by compact
tissue with high cell densities, whereas necrosis is characterized by
increased eosin staining and a bulky extracellular matrix. In
sections of the heart, capillaries and myocardial tissues were
homogeneously distributed. CD31-positive vessels were found in
close proximity to cardiomyocytes (Figure 2A, B). In contrast, the
capillary densities in tumor sections were lower and vessels were
predominantly found in the viable outer borders, but not in the
necrotic center of the tumor (Figure 2C, D). In line with these
findings, the yield of ECs derived from heart and lung tissues was
much higher compared to that of tumors and repair blastemas
(Figure 3A, B).
An important feature of the newly established method is that
comparable amounts of viable, primary microvascular ECs that
became adherent to plastic could be isolated from tumor and
normal tissues of young (5 weeks old) and old mice (up to 100
weeks old) (Table 1). Repeated isolation procedures revealed that it
was possible to isolate approximately 0.456106 CD31-positive
ECs from one heart, approximately 36106 CD31-positive ECs
from one lung, approximately 0.0256106 CD31-positive ECs
from one repair blastema and approximately 0.16106 CD31-
positive ECs from one tumor (Figure 3A, B).
ECs Derived from Heart, Lung, Repair Blastema and
Tumor Differ in Size
After digestion and magnetic bead separation of CD31-positive
and CD31-negative cells, primary ECs were inspected microscop-
ically. In most cases, ECs derived from the heart and lung bound
2–5 micro-beads (Figure 4A), whereas ECs derived from repair
blastema and tumors (CT26, B16-F0) bound more than 20
beads (Figure 4B, C). After biotin-streptavidin competition most
ECs were completely separated from the magnetic beads
(Figure 4D–F). The size of ECs from repair blastema and both
tumors were twice the size of ECs derived from normal tissues
(heart, lung). The diameter of heart and lung ECs ranged between
1.5 and 2 mm, whereas that of repair blastema and tumors ECs
ranged from 3 to 4 mm. Determination of the height of the
forward scatter (FSC-height) by flow cytometry (Figure 4G, H)
confirmed that the mean FSC-height of ECs from repair blastema
(35067) and tumors of different entities (CT26:400640, B16-
F0:437617) were about twice the size of ECs derived from heart
(22566) and lung (18966) tissues. The purity of ECs derived from
heart, lung and tumors was almost 100%.
Typical EC Cell Surface Markers Differ on Primary ECs of
Different Origins
Primary ECs directly after isolation from heart, lung, repair
blastema and tumor were characterized by flow cytometric
analysis using EC-specific antibodies directed against CD31,
CD105, CD144, CD34, CD54 and CD102. The leukocyte
marker CD45, which was used as control, was not detectable on
the population of separated ECs (data not shown). A representa-
tive histogram of each antibody staining pattern is depicted in
Figure 5A, a summary of the proportion of positively stained cells
in Figure 5B and the mean fluorescence intensity values in
Figure 5C are illustrated. The proportion of cells stained positively
for CD31, CD105, CD144, CD34, CD54 and CD102 is nearly
100% (9464) independent of the origin of the tissue from which
the ECs were generated. In contrast, the proportion of the
proliferation marker CD61 was high on tumor ECs (9664) and
low on heart ECs (3067). For the analysis of the ECs derived from
the repair blastema, all CD31-negative cells were removed using a
special gating-strategy. For this, only CD31-positive cells were
visualized in the histograms. In general, the cell surface density of
typical EC markers is higher in ECs derived from tumors than that
of normal (heart, lung) tissues, except for CD144. The marker
densities of CD31 (p= 0.006), CD105 (p = 0.0004), CD34
(p = 0.0005), CD54 (p= 0.03) and CD102 (p= 0.001) were all
significantly increased (two to four-fold) in tumors as compared to
ECs derived from normal tissue (Figure 5C). The expression
density of CD31 (p = 0.007) on ECs derived from repair blastema
was six-fold higher and that of CD105 (p,0.001) twice as high as
that found on normal (heart, lung) tissues. The expression density
of CD34 on repair blastema ECs was similar to that found on
heart or lung ECs, whereas the expression density of CD102 was
more similar to that seen in tumor ECs. Furthermore, ECs from
the repair blastema show a two-fold higher expression of CD144
(p = 0.01) and a five-fold higher expression density of CD54
(p = 0.1) compared to that of ECs from normal tissues (heart and
lung).
Comparative flow cytometric analysis revealed that - except for
the case of CD144 (360683 vs 24466) - the density (mfi) of typical
cell surface markers of ECs such as CD31 (8666 vs 8762), CD105
(153611 vs 155617), CD34 (2261 vs 2261), CD54 (73620 vs
84611), CD102 (128614 vs 137618) were expressed at similar
densities on ECs of hearts of young (5 weeks) and old (85 weeks)
mice (Table 2). This suggests that expression patterns are organ
specific and remain stable on ECs of young and old mice. The
density of the EC marker CD144 which enables tight junctions is
substantially higher in ECs of young mice compared to that of old
mice. This might be related to the fact that the microvasculature
becomes leaky in aged mice.
The B16-F0 tumors grow faster compared to CT26 tumors
in vivo (Figure 6A). The mean doubling times for CT26 and B16-
F0 tumors was 3.6 and 1.9 days (p,0.001), respectively
(Figure 6B). The expression densities of the EC markers CD31
Adhesion Molecules of Primary Endothelial Cells
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(p = 0.002), CD105 (p= 0.002) and CD34 (p= 0.01) were higher
on ECs derived from fast-growing B16-F0 tumors, whereas the
expression densities of the cellular adhesion molecule CD54
(p,0.05) and CD102 (p= 0.008) were found to be elevated in the
slow-growing CT26 tumor (Figure 6C).
Comparative in vitro immunofluorescence studies showed that
the fluorescence intensity of CD31 and isolectin B4 on heart ECs
(Figure 7B, E) was much weaker compared to that on tumor ECs
(Figure 7C, F). As a control, both markers were also used to stain
the murine endothelial cell line H5V (Figure 7A, D) since this
reflects more exactly the staining pattern of the tumor than the
normal primary ECs.
The Morphology and Migration of Normal and Tumor
Derived ECs Differ in vitro
Primary ECs derived from normal (heart) and tumor (B16-F0)
tissues of mice became adherent 1–2 days after seeding (Figure 8A,
B) and the diameter of ECs increased over the following 5 days
until the cells reached 100% confluence (Figure 8C, D). In contrast
to ECs derived from normal tissues, adherent tumor ECs were
found to be larger, to spread faster and to distribute in a more
chaotic pattern compared to those of normal tissues (heart). The
migratory capacity of heart ECs (134668 mm) is significantly
lower compared to that of tumor ECs (1996108 mm) (Figure 8I).
Although heart and tumor ECs became confluent cell divisions
were, as expected, not detectable (video S2, S3), in contrast to the
endothelial cell line H5V (video S1).
Normal But not Tumor Derived ECs Align Under Flow
Conditions
The cultivation of primary heart and tumor ECs under
permanent shear stress allows the physiological conditions in
blood vessels to be simulated. Therefore, 2 days after allowing the
cells to attach, ECs were cultured under constant flow conditions
using the IBIDI system. To avoid detachment of cells the flow was
started at a rate of 2 ml/min for the first day, after which it was
increased to 4 ml/min. After two days, heart ECs started to
elongate in the direction of the flow. Four days later most heart
Figure 2. Localization of necrosis/apoptosis-fraction and capillaries in heart and tumor (B16-F0, size between 0.3–0.4 cm3). (A, C)
H&E staining of heart and tumor, respectively. Arrows indicate the fraction of necrotic/apoptotic areas. (B, D) CD31 immunostaining of heart and
tumor, respectively. Arrows indicate CD31-positive ECs (red).
doi:10.1371/journal.pone.0091808.g002
Figure 3. Weight of various tissues and counts of isolated ECs. (A) Summary of the total weight of separate tissues; weight of heart (n = 10)
and lung (n = 3) taken from 13–15 week-old female mice; weight of repair blastemas (n = 10) taken from a balloon which was induced by using
Freund’s adjuvant/PBS-emulsion; weight of CT26 (n = 10) and B16-F0 (n = 10) tumors which were taken when the size was ranging between 0.3 and
0.4 cm3. (B) Corresponding isolated EC counts were calculated per 100 mg tissue.
doi:10.1371/journal.pone.0091808.g003
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Table 1. Number of viable heart ECs, heart weight and EC adherence after two days as a function of mice age (n = 2).
age of mouse
[weeks] sex weight of heart [g]
ECs counts directly
after isolation
total adherent ECs
after 2 days
5 f 0.07 350,000 60,000
20 f 0.11 400,000 40,000
50 f 0.12 490,000 40,000
100 m 0.14 550,000 50,000
doi:10.1371/journal.pone.0091808.t001
Figure 4. Size of primary ECs isolated from different tissues. (A–C) Isolated ECs from heart, repair blastema and B16-F0 with bound
Dynabeads. Arrows indicate specific binding of corresponding CD31-positive ECs to Dynabeads. (D–F) Isolated ECs from heart, repair blastema and
B16-F0 after biotin-streptavidin competition without any bound Dynabeads. (G, H) Mean of the forward scatter (FSC) from CD31+ cells isolated from
heart (n = 4), lung (n = 3), repair blastema (n = 2), CT26 (n = 4) and B16-F0 (n = 4) measured using flow cytometry. Asteriks represent significantly
different values (p** #0.01; p*** #0.001).
doi:10.1371/journal.pone.0091808.g004
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ECs showed an alignment in the direction of the flow (Figure 8E).
In contrast, ECs derived from tumors did not align in the direction
of the flow (Figure 8F).
Primary ECs Derived from Normal and Tumor Tissues
Differ in Their Capacity to form Tubes
Due to the larger size of tumor ECs compared to normal tissue
ECs, a higher number of heart (80,000 cells/well) than tumor
(20,000 cells/well) ECs was seeded into the matrigel. The numbers
used mirror the minimum number of cells that are required to
allow a tube formation within a defined area (Figure 8G, H).
Tubes formed by tumor ECs show a significantly smaller number
of branching points and loops (58616, 1566) per image
compared to that of ECs derived from heart tissues (17666,
6868) (Figure 8J, K).
Discussion
Previously characterizations of primary ECs in vitro were based
on ECs isolated from young mice within the age range of a few
days up to two weeks. ECs derived from older mice (.2 weeks) did
not become adherent, could not be maintained or expanded in cell
culture, and underwent apoptotic cell death within a few days. The
standard method for isolation of ECs is the use of magnetic beads
that are coupled with a specific antibody directed against EC cell
markers. However, beads bound to isolated ECs represent a steric
disruption, and thus prevent attachment of freshly isolated primary
ECs to plastic surfaces, thus disturbing subsequent experiments.
Up to now, ECs could only be isolated from growing tissues of
very young mice that have the capacity to proliferate and
therefore, have the chance to get rid of the attached beads with
increasing cell divisions. A comparative analysis of cell surface
markers by flow cytometry is only possible after the beads have
been detached from the ECs. The results of analysis using these
in vitro cultured ECs may not be representative of the functional
status of normal ECs in vivo, directly after their isolation. Even
HUVECs and transformed endothelial cell lines such as H5V
provide limited results, since their doubling time in vitro does not
reflect the very low proliferation rate of ECs in healthy tissues of
adult mice [3]. In contrast, the proliferation rate of ECs under
pathological conditions such as wound healing, inflammation and
tumors is high. It has therefore been assumed that proteins
expressed in ECs of resting and growing tissues may be different.
By using the technique described in this paper, primary ECs could
be isolated from young and old mice in the absence of attached
micro-beads in order to characterize them in the stationary phase
without many cell divisions since isolation, in vitro. In the present
study, heart and lung were used as examples of stable, non-
proliferating normal tissues, the repair blastema as a rapidly
proliferating normal tissue, and CT26 and B16-F0 tumors as
proliferating malignant tissues. Isolated cells could be clearly
identified as ECs from each individual tissue due to the expression
of a variety of different typical EC surface markers such as CD31,
CD105, CD144, CD34, CD54 and CD102. Many studies have
used only one marker for the characterization of ECs. This is
however, not sufficient to characterize ECs because each
individual marker alone can also be expressed by other cell types.
The platelet endothelial cell adhesion molecule 1 (PECAM-1)/
CD31 for example is also expressed by platelets, monocytes,
macrophages and neutrophils in addition to ECs [11–13].
Endoglin/CD105 is expressed on vascular ECs, hematopoietic
cells and on several different normal and tumor cell types [14].
Vascular endothelial (VE)-cadherin/CD144 is a specific adhesion
molecule of ECs and the major component of adherent junctions
[15,16]. Sialomucin/CD34 is mainly expressed by hematopoietic
progenitor cells and by ECs from blood vessels, but not by ECs
from lymphatic vessels [17–19]. ICAM-1/CD54 is expressed
constitutively at low levels on vascular ECs and also on leukocytes
[20]. ICAM-2/CD102 is expressed constitutively on lymphocytes,
monocytes, platelets and ECs. These data indicate that the
identification of ECs requires the staining of the cells with more
than just one antibody. All antibodies depicting markers which are
typical for ECs were expressed on nearly 100% of the isolated
ECs, irrespectively of the tissue from which they were derived,
whereas CD61, a proliferation marker was expressed highly only
on ECs that were derived from proliferating tissues.
The expression density of angiogenesis-related markers such as
CD31, CD105, CD144, and CD102 is higher in freshly isolated
ECs of proliferating tissues (tumors, repair blastema) as compared
to non-proliferating normal tissues such as heart and lung. Even
so, the expression of the stemness-related marker CD34 is elevated
in tumor-derived ECs, but not in that of repair blastemas, whereas
the adhesion molecule CD54 was found to be elevated in ECs of
benign and malignant proliferating tissues but not in non-
proliferating normal tissues. The highest density of CD31 and
CD144 was found in ECs isolated from the repair blastema, which
may account for the very rapid angiogenesis exhibited by this
tissue.
Primary ECs isolated from CD31 deficient mice showed a
decreased cell migration and a reduced capillary morphogenesis
[21]. Blocking of CD31 inhibited the growth and vascularization
of tumors in mice and inhibited the EC tube formation, in vitro
[22]. However, CD31 knockout mice developed a normal
functional vascular system during embryonic development, but a
Figure 5. Identification and characterization of ECs derived from different origin. (A) Identification of control EC line H5V and primary ECs
isolated from heart, lung, repair blastema, CT26 and B16-F0 using flow cytometry with EC-specific antibodies directed against CD31, CD105, CD144,
CD34, CD54 and CD102. (B, C) Proportion of positively stained cells and mean fluorescence intensity values (mfi) (CD31, CD61, CD105, CD144, CD34,
CD54, CD102) from normal ECs (heart (n = 5), lung (n = 3)), repair blastema ECs (n = 2) and tumor ECs (CT26 (n = 3), B16-F0 (n = 3)). Asteriks represent
significantly different values (p* #0.05; p** #0.01; p*** #0.001).
doi:10.1371/journal.pone.0091808.g005
Table 2. Mean fluorescence intensity (mfi) of CD31, CD105, CD144, CD34, CD54 and CD102 of heart ECs in dependency of the age
of mice (n = 2).
age of mice [weeks] mfi CD31 mfi CD105 mfi CD144 mfi CD34 mfi CD54 mfi CD102
5 8666 153611 360683 2261 73620 128614
85 8762 155617 24466 2261 84611 137618
doi:10.1371/journal.pone.0091808.t002
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decreased angiogenesis in inflammation [23]. CD61 was upregu-
lated in tumor vasculature and it was shown that depletion of
CD61 transiently inhibited tumor growth and angiogenesis in mice
[24,25]. CD105 expression is increased in ECs during wound
healing, developing embryos, inflammatory tissues and solid
tumors [26,27]. All of these processes are involved in angiogenesis
and are associated with the receptor of the transforming growth
factor-b complex (TGF-b). A high expression of CD105 on tumor
ECs correlates with a reduced survival of patients [28,29]. ECs
from CD144-deficient mice form primitive vascular structures,
which are unstable during further development and result in
embryonic death [30–32]. Furthermore, antibodies against
Figure 6. Differences in expression of EC markers derived from slow- and fast-growing tumors (CT26 and B16-F0). (A, B) Growth
curves and doubling times of CT26 (n = 15) and B16-F0 (n = 15), in vivo. Asteriks represent significantly different values (p* #0.05; p*** #0.001). (C)
Mean fluorescence intensity values (CD31, CD105, CD144, CD34, CD54, CD102) from slow-growing tumor ECs (CT26 (n = 3)) and fast-growing tumor
ECs (B16-F0 (n = 3)). Asteriks represent significantly different values (p* #0.05; p** #0.01).
doi:10.1371/journal.pone.0091808.g006
Figure 7. Identification of ECs by immunostaining. (A–C) CD31 staining of H5V, primary heart and tumor ECs (B16-F0). (D–F) Isolectin B4-
staining of H5V, primary heart and tumor ECs (B16-F0).
doi:10.1371/journal.pone.0091808.g007
Adhesion Molecules of Primary Endothelial Cells
PLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e91808
CD144 reduced angiogenesis and tumor growth in vivo [33–35].
The present study shows that high expression densities of CD31,
CD61, CD105 and CD144 on freshly isolated ECs correlate with
increased angiogenic capacity. Additionally, CD105 has been
described as being capable of preventing apoptosis in hypoxic ECs
and leading to an enhanced survival of ECs under hypoxic stress
[36]. This may be the reason that CD105 is expressed at higher
levels on tumor ECs compared to ECs isolated from repair
blastema.
The expression density of CD34 in mouse embryonic blood
vessels is high in pre-endothelial cells and in vessels formed by
vasculogenesis and angiogenesis, but low in vessels, which are
involved in the process of coalescence to form larger vessels [37].
In the early phase, CD34 knockout mice with transplanted B16-F1
melanoma cells showed a decreased, and then later an increased
tumor growth caused by a reduced capacity of CD342/2
hematopoietic cells [38]. In this present study the fact that CD34 is
expressed at a higher level on tumor ECs could be due to
Figure 8. Phenotypic and functional characteristics of primary heart and tumor ECs (B16-F0), in vitro. (A, B) Adherent heart and tumor
ECs after 2 days. (C, D) Adherent heart and tumor ECs after 7 days. (E, F) Heart and tumor ECs under flow conditions (4 ml/min) after 4 days. Before
starting the flow cells were incubated for 2 days under static conditions and 1 day under low flow conditions (2 ml/min). Arrows indicate flow
direction. (G, H) Vascular tube formation of heart and tumor ECs on matrigel. (I) Migratory capacity of heart and tumor ECs. Asteriks represent
significantly different values (p** #0.01). (J, K) Number of total branching points and total loops of heart and tumor ECs on matrigel. Asteriks
represent significantly different values (p* #0.05).
doi:10.1371/journal.pone.0091808.g008
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circulating endothelial progenitor cells, which might be involved in
the vasculogenesis of the tumor.
CD54 is also up-regulated by inflammatory cytokines in various
cell types and may increase leukocyte extravasation in inflamma-
tion [20,39]. CD54 inhibition in mouse melanomas using CD54
antisense oligonucleotides resulted in fewer metastases in the lungs
[40]. Antibodies against CD54 also blocked the invasion of
metastatic human breast cancer cells in vitro [41]. In contrast to
CD54, the expression of CD102 is not increased by inflammatory
cytokines [42]. Experiments in CD102-deficient mice have shown
that CD102 on ECs is required for angiogenesis and is involved in
survival and cell migration, but not in EC proliferation [43]. The
present study shows that the expression of CD102 is increased on
ECs from growing tumors and repair blastemas, whereas the
expression of CD54 is increased mainly in physiological wound
healing.
The higher expression of CD31, CD105 and CD34 on ECs
from the B16-F0 tumor correlates with the faster tumor growth
compared to that of CT26 tumors. In contrast, the higher
expression of CD54 and CD102 on ECs from CT26 correlates
with the higher metastatic behavior of CT26 compared to B16-F0
in lung, when cells were subcutaneously injected in syngeneic mice
[44,45].
Tumor ECs are larger, have a significantly higher migratory
capacity and distribute in a more chaotic pattern in cell culture
compared to ECs derived from normal tissue, in vitro. Primary ECs
from non-proliferating and proliferating tissue differ in their
functional properties, in vitro. Tube formation assays showed that
tumor ECs have a smaller number of branching points and loops
compared to that of normal ECs and, in contrast to normal tissue
ECs, tumor-derived ECs show no tendency to align under flow
conditions.
In summary, the novel method presented here, provides a
powerful tool for the purification of viable primary microvascular
ECs of different origins which can be used to analyze organ-
specific immunological interactions and functional changes in the
interplay of existing and evolving ECs from benign and malignant
tissues.
Our results provide evidence indicating that freshly isolated
primary ECs from different tissues differ in many respects. These
differences may be related to the different functions of the
microvasculature of the tissues from which the ECs have been
isolated. The expression density of the different markers on ECs
might have an impact on the proliferation rate of ECs, the
permeability for metastasis or the involvement of circulating
endothelial progenitor cells.
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